Department of Neurology, H2.216, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, the Netherlands.
Stroke. 2011 Sep;42(9):2515-20. doi: 10.1161/STROKEAHA.111.617282. Epub 2011 Jul 28.
The safety and efficacy of thrombolysis in cervical artery dissection (CAD) are controversial. The aim of this meta-analysis was to pool all individual patient data and provide a valid estimate of safety and outcome of thrombolysis in CAD.
We performed a systematic literature search on intravenous and intra-arterial thrombolysis in CAD. We calculated the rates of pooled symptomatic intracranial hemorrhage and mortality and indirectly compared them with matched controls from the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register. We applied multivariate regression models to identify predictors of excellent (modified Rankin Scale=0 to 1) and favorable (modified Rankin Scale=0 to 2) outcome.
We obtained individual patient data of 180 patients from 14 retrospective series and 22 case reports. Patients were predominantly female (68%), with a mean±SD age of 46±11 years. Most patients presented with severe stroke (median National Institutes of Health Stroke Scale score=16). Treatment was intravenous thrombolysis in 67% and intra-arterial thrombolysis in 33%. Median follow-up was 3 months. The pooled symptomatic intracranial hemorrhage rate was 3.1% (95% CI, 1.3 to 7.2). Overall mortality was 8.1% (95% CI, 4.9 to 13.2), and 41.0% (95% CI, 31.4 to 51.4) had an excellent outcome. Stroke severity was a strong predictor of outcome. Overlapping confidence intervals of end points indicated no relevant differences with matched controls from the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register.
Safety and outcome of thrombolysis in patients with CAD-related stroke appear similar to those for stroke from all causes. Based on our findings, thrombolysis should not be withheld in patients with CAD.
颈内动脉夹层(CAD)患者接受溶栓治疗的安全性和疗效仍存在争议。本荟萃分析旨在汇总所有患者的个体数据,以提供 CAD 患者溶栓治疗安全性和结局的有效评估。
我们对 CAD 患者静脉溶栓和动脉内溶栓进行了系统的文献检索。我们计算了汇总后的症状性颅内出血和死亡率,并与 Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register 中的匹配对照组进行间接比较。我们应用多变量回归模型来识别良好结局(改良 Rankin 量表评分为 0 至 1)和有利结局(改良 Rankin 量表评分为 0 至 2)的预测因素。
我们从 14 项回顾性研究和 22 份病例报告中获得了 180 例患者的个体数据。患者主要为女性(68%),平均年龄±标准差为 46±11 岁。大多数患者表现为严重脑卒中(中位数国立卫生研究院卒中量表评分=16)。治疗方法为静脉溶栓者占 67%,动脉内溶栓者占 33%。中位随访时间为 3 个月。汇总后的症状性颅内出血发生率为 3.1%(95%可信区间,1.3%至 7.2%)。总体死亡率为 8.1%(95%可信区间,4.9%至 13.2%),41.0%(95%可信区间,31.4%至 51.4%)患者取得了良好结局。卒中严重程度是结局的重要预测因素。终点的置信区间重叠表明,与来自 Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register 的匹配对照组相比,没有明显差异。
CAD 相关卒中患者接受溶栓治疗的安全性和结局似乎与其他病因所致卒中患者相似。基于我们的研究结果,不应拒绝 CAD 患者接受溶栓治疗。